BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36245224)

  • 1. Impact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study.
    Seino M; Nagase S; Ohta T; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kaneuchi M; Enomoto T; Mikami M
    J Gynecol Oncol; 2023 Jan; 34(1):e4. PubMed ID: 36245224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix.
    Lee SW; Lim KT; Bae DS; Park SY; Kim YT; Kim KR; Nam JH
    Gynecol Obstet Invest; 2015; 79(3):172-8. PubMed ID: 25500455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
    Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
    Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
    Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
    Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
    Lee JM; Lee KB; Nam JH; Ryu SY; Bae DS; Park JT; Kim SC; Cha SD; Kim KR; Song SY; Kang SB
    Ann Oncol; 2008 Feb; 19(2):321-6. PubMed ID: 17962205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Aspects of Small Cell Neuroendocrine Carcinoma of the Uterine Cervix: a Multicenter Retrospective Study and Meta-Analysis.
    Xu F; Ma J; Yi H; Hu H; Fan L; Wu P; Chen X; Wu X; Yu L; Xing H; Wang W
    Cell Physiol Biochem; 2018; 50(3):1113-1122. PubMed ID: 30355937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study.
    Lee SW; Nam JH; Kim DY; Kim JH; Kim KR; Kim YM; Kim YT
    Int J Gynecol Cancer; 2010 Apr; 20(3):411-6. PubMed ID: 20375806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of the recurrence of early stage bulky cervical carcinoma].
    Hu JL; Wu LY; Li XG; Zhang R; Li N; Yao HW
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):378-81. PubMed ID: 22883461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Pei X; Xiang L; Ye S; He T; Cheng Y; Yang W; Wu X; Yang H
    Gynecol Oncol; 2017 Dec; 147(3):589-596. PubMed ID: 28954697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes.
    Ishikawa M; Kasamatsu T; Tsuda H; Fukunaga M; Sakamoto A; Kaku T; Kato T; Takahashi K; Ariyoshi K; Suzuki K; Arimoto T; Matsumoto Y; Nakai H; Inoue T; Yokoyama M; Kawabata T; Kodama S; Miyamoto T; Takano M; Yaegashi N
    Gynecol Oncol; 2019 Dec; 155(3):444-451. PubMed ID: 31635755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
    Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
    Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer.
    Mikami M; Shida M; Shibata T; Katabuchi H; Kigawa J; Aoki D; Yaegashi N
    J Gynecol Oncol; 2018 Mar; 29(2):e23. PubMed ID: 29400016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses.
    Lin LM; Lin Q; Liu J; Chu KX; Huang YX; Zhang ZK; Li T; Dai YQ; Li JL
    Cancer Med; 2020 Sep; 9(18):6524-6532. PubMed ID: 32705800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG-G1201).
    Mori T; Makino H; Okubo T; Fujiwara Y; Sawada M; Kuroboshi H; Tsubamoto H; Murakoshi H; Motohashi T; Kitawaki J; Ito K
    J Obstet Gynaecol Res; 2019 Mar; 45(3):671-678. PubMed ID: 30575239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases.
    Lan-Fang L; Hai-Yan S; Zuo-Ming Y; Jian-Qing Z; Ya-Qing C
    Eur J Gynaecol Oncol; 2012; 33(1):68-73. PubMed ID: 22439409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer.
    Mabuchi S; Komura N; Sasano T; Sakata M; Matsuzaki S; Hisa T; Kamiura S; Morishima T; Miyashiro I
    Curr Oncol; 2023 Oct; 30(11):9428-9436. PubMed ID: 37999102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group.
    Mikami M; Aoki Y; Sakamoto M; Shimada M; Takeshima N; Fujiwara H; Matsumoto T; Kita T; Takizawa K;
    Int J Gynecol Cancer; 2014 Sep; 24(7):1333-40. PubMed ID: 25078340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Ebina Y; Yamagami W; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Enomoto T; Mikami M
    Gynecol Oncol; 2021 Nov; 163(2):269-273. PubMed ID: 34454726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.
    Ishikawa M; Kasamatsu T; Tsuda H; Fukunaga M; Sakamoto A; Kaku T; Nakanishi T; Hasumi Y; Iwata T; Baba T; Nogawa T; Kudaka W; Kaneda H; Ono S; Saito F; Taniguchi Y; Okada S; Mizuno M; Onda T; Yaegashi N
    Gynecol Oncol; 2018 Jan; 148(1):139-146. PubMed ID: 29113721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study.
    Kagabu M; Nagasawa T; Tatsuki S; Fukagawa Y; Tomabechi H; Takatori E; Kaido Y; Shoji T; Baba T
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34072478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.